三种奈达铂联合化疗方案治疗晚期非小细胞肺癌的效果及成本效益比较  

Comparison of the efficacy and cost-effectiveness of three kinds of nedaplatin combined chemotherapy regimens in the treatment of advanced non-small cell lung cancer

作　　者：何旭[1] 汤利荣[1] 赵强[1] HE Xu;TANG Li-rong;ZHAO Qiang(Pharmacy Department,Hanzhong Central Hospital,Hanzhong 723000,China)

机构地区：[1]汉中市中心医院药剂科

出　　处：《临床医学研究与实践》2020年第4期20-22,36,共4页Clinical Research and Practice

摘　　要：目的探究奈达铂分别联合多西他赛、吉西他滨与培美曲塞二钠治疗晚期非小细胞肺癌(NSCLC)的临床效果及成本效益。方法收集2017年1月至2019年5月我院的105例确诊为晚期NSCLC患者的资料,并依据治疗方案的不同将其分为DP组(多西他赛+奈达铂)、GP组(吉西他滨+奈达铂)及PP组(培美曲塞二钠+奈达铂),各35例。比较三组患者的临床疗效、不良反应、治疗成本及成本-效益。结果三组患者的RR无显著差异(P>0.05);三组患者的中位PFS无显著差异(P>0.05);PP组的DCR显著高于DP组及GP组,差异具有统计学意义(P<0.05)。Ⅲ度和Ⅳ度不良反应中,三组患者血小板减少、恶心呕吐发生情况有显著差异(P<0.05),血小板减少:PP组<DP组<GP组,恶心呕吐:PP组<GP组<DP组。Ⅲ度和Ⅳ度不良反应中,三组患者白细胞减少、肝功能异常、腹泻发生情况无显著差异(P>0.05)。每获得1个单位(1个月)PFS,DP组的花费为12890.42元,GP组的花费为14003.56元,PP组的花费为17230.11元。结论PP方案在疾病控制率和不良反应方面优于DP、GP方案;DP方案的成本效益优于GP、PP方案。Objective To explore the clinical effect and cost-effectiveness of nedaplatin combined with docetaxel,gemcitabine and pemetrexed disodium in the treatment of advanced non-small cell lung cancer(NSCLC).Methods The data of 105 patients with advanced NSCLC diagnosed in our hospital from January 2017 to May 2019 were collected and divided into DP group(docetaxel+nedaplatin),GP group(gemcitabine+nedaplatin)and PP group(pemetrexed disodium+nedaplatin),with 35 cases in each group.The clinical effects,adverse reactions,treatment costs and cost-effectiveness of the three groups were compared.Results There was no significant difference in RR between the three groups(P>0.05);there was no significant difference in median PFS among the three groups(P>0.05);DCR in the PP group was significantly higher than that in the DP group and GP group,the differences were statistically significant(P<0.05).In theⅢandⅣdegree adverse reactions,there were significant differences in thrombocytopenia,nausea and vomiting among the three groups(P<0.05),thrombocytopenia:PP group<DP group<GP group,nausea and vomiting:PP group<GP group<DP group.In theⅢandⅣdegree adverse reactions,there were no significant differences in the leucopenia,abnormal liver function and diarrhea among the three groups(P>0.05).The cost of the DP group is 12890.42 yuan,GP group is 14003.56 yuan and PP group is 17230.11 yuan for each PFS unit(1 month).Conclusion PP regimen is better than DP and GP regimens in disease control rate and adverse reactions,and DP regimen is better than GP and PP regimens in cost-effectiveness.

关 键 词：非小细胞肺癌 奈达铂 多西他赛 吉西他滨 培美曲塞二钠 不良反应 成本效益 

分 类 号：R734.2[医药卫生—肿瘤]